Replies to post #40630 on SiNtx Technologies Inc (SINT)

[boston745]

Hmm, pot calling the kettle black syndrome?

Nope. Madg claimed i was full of shit for claiming that Zimmer was a stakeholder in Sintx and that i was guaranteeing an acquisition. I addressed those claims and asked madg a question in return for which he has yet to respond to. In response to my response to Madg, Mictrade jumps into the conversation, changes the subject, and attacks my motives for simply showing evidence of why i claim Zimmer is a stakeholder in Sintx and why i believe that Zimmer will use Sintx for its strategic interests whether thats to acquire it or something more akin to what Eli did with Bristol Myers. Thus his post falls under disinformation because he's the one that changed the subject and did not in fact address any of the points i made to Madg in my replies to him. Incidently, you arent addressing my points either. Why are you claiming im the one who changed the subject when clearly MicTrade did?

How about you joe, will you answer my questions? Can Sintx and/or Zimmer include the testing data in the following two links in a submission to the FDA to receive clearance to commercialize a product together one day? Just to clarify, im not saying the data in this testing is enough for clearance. Im just asking could this testing data be part of a submission to the FDA of a product or products containing IP from both companies? If the answer is Yes, then Zimmer is a stakeholder.

https://ir.sintx.com/news-events/press-releases/detail/95/amedica-announces-results-of-independent-femoral-head-wear
https://www.sciencedirect.com/science/article/abs/pii/S1751616119309099

Amedica and Zimmer-Biomet (Tokyo Office) provided the femoral heads and acetabular liners; however, neither company actively sponsored the research.

Do you agree with my statement that Zimmer Biomet became a stakeholder the moment it allowed its IP to be tested with Sintx IP? It became an interested party in the test results. Thats what makes them a stakeholder!
I could, and have, argued that they have been a stakeholder since Sintx founding, (when you factor Centerpulse has been since Sintx began and Zimmer acquired Centerpulse) based on shared personnel, but the above is simple and more straightforward.

Joe, is the information below factual outside my belief that Eli Lilly and Bristol Myers made a deal behind the scenes and Icahn provided public cover for their deal? If you want you can comment on my opinion on behind the scenes deal. One last question if you wouldn't mind answering. Why is it when Sintx filed the IPO in 2007 it included the information that Zimmer purchased Centerpulse while Dr Link was CEO, but omitted that fact from the 2013 IPO?

You answer my questions ill answer yours...although im pretty sure i already answered this one previously.

========================================

Sintx - Zimmer connection in personnel is greater than this list. This list is to illustrate how Zimmer has had personnel leading Sintx since its founding connected to it and this means it can influence direction while protecting its interests.

Dr. Hofmann, MD -Co-Founder of Sintx (then Amedica) was a surgeon consultant for Centerpulse and then Zimmer
Dr. Link, PHD - Chariman of Sintx until 2014 was CEO of Centerpulse when Zimmer acquired it.
Dr. S Bal, MD - Chairman/CEO. Surgeon Consultant for Zimmer from 2002 to at least 2014.

https://www.sec.gov/Archives/edgar/data/1269026/000119312507120692/ds1.htm pg 73 &74
https://www.sec.gov/Archives/edgar/data/1269026/000119312513435409/d593074ds1.htm pg 89/90


========================================

Amylin - Eli connection via personnel

Howard E. Greene Jr - Sells Hybritech to Eli Lilly 1986. Founds Amylin 1987
Jospeh Cook - 28 year Eli Lilly Veteran joins 1994. Becomes Chairman/CEO 1998. Steps down as CEO in 2003. Removed as Chairman 2009 by Icahn
Ginger L. Graham - Exective at Eli Lilly until Lilly divests its medical device business in 1993 joins Cook on Amylin's board in 1994. Took over as CEO of Amylin when Cook stepped down in 2003.

Eli Lilly acquires ImClone 2008, partnered with Bristol Myers since 2002, with Carl Icahn aiding in purchase. Icahn then removes Cook as Chairman with Graham stepping down in 2009 before selling Amylin to Bristol Myers in 2012. In my opinion Eli Lilly and Bristol Myers did a trade of sorts behind the scenes both acquiring businesses each were partnered with and used Carl Icahn to provide the public cover for the behind the curtain deal.

https://www.latimes.com/archives/la-xpm-1986-03-19-fi-22814-story.html
https://www.twst.com/interview/joe-c-cook-jr-amylin-pharmaceuticals-amln
https://www.colorado.edu/biofrontiers/ginger-l-graham